Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sanja Dacic, William D. Travis, Jennifer Margaret Giltnane, John Abel, Filip Kos, Stephanie Hilz, Stephanie Hennek, Junya Fujimoto, Lynette M. Sholl, Farah Khalil, Jon Ritter, Massimo D'Apuzzo, Jay M. Lee, Valerie W. Rusch, David Paul Carbone, Alan Nicholas, Ann Johnson, Katja Schulze, Mark G. Kris, Ignacio Ivan Wistuba
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Memorial Sloan Kettering Cancer Center, Genentech, PathAI (United States), The University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Moffitt Cancer Center, Washington University in St. Louis, City Of Hope National Medical Center, University of California, Los Angeles, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Topic: AI in cancer detection
Subfield: Artificial Intelligence
Field: Computer Science
Domain: Physical Sciences
Open Access status: closed
Funder: F. Hoffmann-La Roche
OpenAlex ID: W3170819568